PANTOPRAZOLE SODIUM ANHYDROUS

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H14F2N3O4S.Na
Molecular Weight	405.352
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PANTOPRAZOLE SODIUM ANHYDROUS

Structure Search

SMILES

[Na+].COC1=CC=NC(C[S+]([O-])C2=NC3=C([N-]2)C=C(OC(F)F)C=C3)=C1OC

InChI

InChIKey=YNWDKZIIWCEDEE-UHFFFAOYSA-N

InChI=1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h3-7,15H,8H2,1-2H3;/q-1;+1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours. Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus for adults and pediatric patients 5 years of age and older caused by gastroesophageal reflux disease. It can be used as a maintenance therapy for long-term use after initial response is obtained, but there have not been any controlled studies about the use of pantoprazole past a duration of 12 months. Pantoprazole may also be used in combination with antibiotics to treat ulcers caused by Helicobacter pylori. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18536934 \| https://www.ncbi.nlm.nih.gov/pubmed/8389196	Inhibitor 8297
Potassium-transporting ATPase 31 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11402494	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis associated with gastroesophageal reflux disease 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000
Zollinger-Ellison syndrome 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8429	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781 substrate 1737	substrate 1037 inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 383 OAT3 642 CYP2C8 911 CYP1A2 1524 CYP2A6 707 CYP2E1 882 P-gp 1461 BCRP 699 CYP2C19 1478 OAT1 599 OATP1B1 788 OATP1B3 706 OCT1 512 OCT2 647 OCT3 150 ALDH1 40 MATE2 263 MATE1 306 OATP2B1 123	CYP2C19 991 P-gp 1537 sulfotransferases 38	CYP1A 56 CYP1A1 108 CYP2C 15

Drug as perpetrator

Target	Modality	Activity
ALDH1 40	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	inconclusive [Activation 22.3872 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19139163/	likely
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6Ilx0Q0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
MATE2 263	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >500 uM]
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	no
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP2C19 1553	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://drug-interactions.medicine.iu.edu/MainTable.aspx \| https://pubmed.ncbi.nlm.nih.gov/21795468/	weak [IC50 93 uM]
P-gp 1650	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.9 uM]
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 2.8 uM]
OCT3 150	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 22.9 uM]
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 30.8 uM]
OAT3 644	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.45 uM]
MATE1 308	inhibitor 3277 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	yes [IC50 43.2 uM]
BCRP 773	inhibitor 3277 Sources: https://go.drugbank.com/articles/A16380 \| https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 5.5 uM]
OAT1 603	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 63.21 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15258107/	yes [Ki 6.5 uM]
CYP1A 121	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=21 Page: (Pharm_P7) 21	yes
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/	yes
CYP2C 34	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
MRP2 475	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OCT3 150	activator 214 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29346&ns=ncit&type=relationship&key=n75796996&b=1&n=0&vse=null Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
P-gp 1537	substrate 3367 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes
sulfotransferases 38	substrate 3367 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=102625707 \| https://pubmed.ncbi.nlm.nih.gov/9165689/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915
ChemicalBook	CB51025809	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51025809
ChemicalBook	CB8129842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8129842
MolPort	MolPort-003-666-752	https://www.molport.com/shop/molecule-link/MolPort-003-666-752
MolPort	MolPort-005-933-577	https://www.molport.com/shop/molecule-link/MolPort-005-933-577
eMolecules	902267	https://www.emolecules.com/cgi-bin/more?vid=902267

PubMed

Title	Date	PubMed
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.	2001	11768559
Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease.	2001	11351143
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].	2001 Apr 15	11387678
Dyspepsia: challenges in diagnosis and selection of treatment.	2001 Aug	11558854
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.	2001 Feb	11232672
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.	2001 Feb	11210394
Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.	2001 Jan-Feb	11413863
Persistent eradication of Helicobacter pylori after systemic politherapy associated with periodontal pockets treatment with metronidazole and calcium sulphate.	2001 Jul-Aug	12067080
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.	2001 Jun	11380323
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.	2001 Jun	11380317
Proton pump inhibitors: a study of GPs' prescribing.	2001 Jun	11356744
Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.	2001 Mar	11240974
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.	2001 Mar 9	11292068
Is there any relationship between functional dyspepsia and chronic gastritis associated with Helicobacter pylori infection?	2001 Mar-Apr	11379362
Proton pump inhibitors and their drug interactions: an evidence-based approach.	2001 May	11396546
Cluster headache without autonomic symptoms?	2001 Nov	11903290
Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.	2001 Nov	11685025
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.	2001 Nov	11683695
Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.	2001 Oct	11718254
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].	2002	12353402
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	2002	12222994
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.	2002	12060043
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].	2002	12043311
Selective colonization by Helicobacter pylori of the deep gastric glands and intracellular canaliculi of parietal cells in the setting of chronic proton pump inhibitor use.	2002 Apr	11943964
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.	2002 Apr	11929403
Nonallergic anaphylaxis to pantoprazole.	2002 Feb	11929432
Protonix. First i.v. proton pump inhibitor approved.	2002 Feb	11924161
Conformational analysis: a new approach by means of chemometrics.	2002 Jan 30	11926199
Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.	2002 Jul-Aug	12143188
Pantoprazole-induced recurrent anaphylactic shock.	2002 Jun	12094902
Intravenous proton pump inhibitors in the critical care setting.	2002 Jun	12072664
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.	2002 Jun	12072662
Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.	2002 Jun	12072661
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.	2002 Jun 22	12077038
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.	2002 Mar	11876710
Acid suppression in healthy subjects following lansoprazole or pantoprazole.	2002 Mar	11876695
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.	2002 Mar	11849125
Combination drug therapy for gastroesophageal reflux disease.	2002 May	11978171
Stability of pantoprazole in an extemporaneously compounded oral liquid.	2002 May 15	12040734
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.	2002 Oct	12352294
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.	2002 Oct 21	12381251
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.	2002 Sep	12395996

Patents

Sample Use Guides

In Vivo Use Guide

Oral use: Short-Term Treatment of Erosive Esophagitis Associated With GERD: 40 mg Once daily for up to 8 weeks; Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: 40 mg Twice daily IV: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days

Route of Administration: Other

In Vitro Use Guide

To determine "ex vivo" gastric mucosa gastric acid secretion, pantoprazole (as DMSO solution diluted with serosal fluid) was added to membrane mucosa liquid in the bath tube. Pantoprazole final concentration in serosal fluidwas 5 mkM, incubation time -- 2.5h. Pantoprazole mediated gastric acid secretion inhibition is 24.3% at 5mkM.

Name

Type

Language

PANTOPRAZOLE SODIUM ANHYDROUS

Common Name

English

PANTOPRAZOLE SODIUM SALT [MI]

Common Name

English

1H-BENZIMIDAZOLE, 6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT (1:1)

Systematic Name

English

Pantoprazole sodium anhydrous [WHO-DD]

Common Name

English

PANTOPRAZOLE SODIUM SALT

Common Name

English

Code System Code Type Description

CAS

138786-67-1